Physician profile
Mary Wilson
NPI 1235872482
$475.71
in general payments reported to CMS, 2019-2025
14 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $87.44 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $97.53 | 2025 | |
| Astellas Pharma US INC | $87.44 | 2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $47.42 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.68 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.10 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.31 | 2025 | Xifaxan |
| Corcept Therapeutics | $24.21 | 2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $23.40 | 2025 | Ultomiris |
| Amphastar Pharmaceuticals, INC. | $21.64 | 2025 | |
| Averitas Pharma INC. | $18.44 | 2025 | Qutenza |
| Exact Sciences Corporation | $18.33 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.29 | 2025 | Caplyta |
| Pfizer INC. | $14.01 | 2025 | |
| Lilly USA, LLC | $13.91 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.